

BRITISH  
PAIN  
SOCIETY  
'22



THE BRITISH  
PAIN SOCIETY  
EXPERTISE WHERE IT MATTERS

BRITISH PAIN SOCIETY  
55<sup>TH</sup> ANNUAL  
SCIENTIFIC  
MEETING

13 - 15 June 2022  
LONDON & ONLINE

Final Programme  
E-book

[www.bpsasm.org](http://www.bpsasm.org)



# CONTENT

WELCOME TO LONDON .....	3
VENUE & FLOORPLANS .....	4
GENERAL INFORMATION .....	6
· Annual Meeting Hours .....	6
· Practical Information within the Meeting Venue .....	6
· Information for Speakers .....	6
· Meeting Materials for Participants .....	6
· Disclaimer .....	7
INVITED SPEAKERS & SESSION CHAIRS .....	8
SCIENTIFIC PROGRAMME .....	9
Monday, June 13, 2022 .....	9
Tuesday June 14, 2022 .....	11
Wednesday, June 15, 2022 .....	13
INDUSTRY SYMPOSIA .....	14
SPONSORS & EXHIBITORS .....	16
INDUSTRY COMPANY PROFILES .....	17



## WELCOME TO LONDON

Dear Colleagues and Friends,

It is our great pleasure to welcome you in London, United Kingdom for the BPS ASM 2022 - **55<sup>th</sup> Annual Scientific Meeting of The British Pain Society**, the very first BPS Meeting to happen in-person after a two-years break because of the pandemic.

Along the past year, we have worked very closely with the BPS Scientific Committee to offer you an exiting and strong Annual Meeting programme.

Besides the high-quality programme of the meeting, we are sure that you will also enjoy the sights and sounds of London and the beauty of summer in the United Kingdom. The area where the meeting will be held, Wembley, is synonymous with football and has witnessed some iconic moments in history. This is the backdrop where we will be holding the meeting and is only a few minutes away by tube to most of the attractions in London.

Hope you will enjoy meeting each other in real life after a long break of virtual events, your time in London  
**WELCOME TO LONDON !**

On behalf of the Council and the Scientific Programme Committee

Dr. Arun Bhaskar  
BPS President

Dr. Stephen Ward  
Scientific Programme Committee Chair



# VENUE & FLOORPLANS

## ANNUAL MEETING VENUE

**Hilton London Wembley**

**Address:** Lakeside Way Wembley, HA9 0BU, United Kingdom

## MEETING SPACES IN THE VENUE & FLOORPLAN


Below are the list of spaces/rooms used for BPS 2022 Annual Meeting. Layouts for each level is following the list. All signages of the Annual Meeting are prepared while using the original room/space names of the Venue. Therefore, you may refer to the signages of the Annual Meeting as well as the general signages within the venue while finding your way around the venue.

<b>Annual Meeting Spaces / Halls</b>	<b>Level</b>	<b>Name of the Space as Used in the Venue Signages</b>
Registration Area	Level 3	Ballroom Foyer
Exhibition Area	Level 3	Ballroom 1 & Ballroom Foyer
Posters Area	Level 3	Ballroom 1 & Ballroom Foyer
Hall A   Plenary Hall	Level 3	Ballroom 2 & 3
Hall B	Level 4	Meeting Room 7 & 8
Hall C	Level 4	Meeting Room 5 & 6
Hall D	Level 4	Meeting Room 1, 2 & 3
Speakers' Ready Room	Level 4	Meeting Room 9 & 10




## VENUE & FLOORPLANS

### 3<sup>RD</sup> FLOOR



Abbott	Nevro
Advanced Medical equipment, LTD	ONCOMFORT S.A.
Althea	Pfizer Ltd
Boston Scientific	Polar Medical Ltd.
BVM Medical	Q Interventional Technologies
Grow Pharma Ltd	Rokshaw Limited
Grünenthal Limited	Sandoz
Lyphe Group	Sonosite
Macromed	Stimwawe Technologies
Mainstay Medical	Stryker
Medical Research Foundation	Thor Photomedicine, Ltd
Medtronic Limited	

### 4<sup>TH</sup> FLOOR





## GENERAL INFORMATION

### ANNUAL MEETING HOURS

#### Registration Desk Opening Hours

13 June 2022	08:00-18:00
14 June 2022	07:00-18:00
15 June 2022	07:00-16:00

#### Exhibition Opening Hours

13 June 2022	09:30-19:00
14 June 2022	09:00-19:10
15 June 2022	09:00-14:00

### PRACTICAL INFORMATION WITHIN THE MEETING VENUE

#### Language of the Annual Meeting

The official language of the BPS ASM 2022 Meeting is English.



#### Wi-Fi Network for Meeting Participants

We are pleased to offer complimentary Wi-Fi access to all BPS ASM 2022 participants

Network Name : **BPS2022ASM**

Password : **BPS2022London**

### INFORMATION FOR SPEAKERS

All speakers are kindly requested to upload their presentations in the Speakers' Ready Room (Meeting Room 9 & 10 on Level 4) at least 2 hours prior to the start time of their session. If the session is the first session in the morning, please upload your presentation the day before

#### Speaker Ready Room Operating Hours:

13 June 2022	07:45-18:00
14 June 2022	07:00-18:00
15 June 2022	07:00-15:30

### MEETING MATERIALS FOR PARTICIPANTS

#### Name Badges

The name badges will be distributed from the Registration Area. All participants are kindly requested to wear their name badges throughout the Annual Meeting.

#### Certificates of Attendance

The certificates of attendance will be sent to all participants after the Annual Meeting via e-mail.

#### Certificates of Presentation

The presenters of oral and poster abstracts will be eligible to get a certificate of presentation which will be sent to the presenters upon request after the Annual Meeting. You may contact the Annual Meeting Secretariat (Ms. Mojca Rodic at [mrodic@kenes.com](mailto:mrodic@kenes.com)) for getting your presentation certificates.

#### Post-Meeting Survey

A post-meeting survey will be sent to all participants after the Annual Meeting. In order to get your CME Credits, you will be required to fill in this survey and submit.



## GENERAL INFORMATION

### Mobile Application

The Annual Meeting mobile application is prepared for you to navigate through the Meeting details with ease and enhance your participation. You may download it through IOS/App Store or Android/ Google Play through the below QR codes.



Download from IOS/App Store



Download from Android/Google Play

Either via QR Code Either via QR Code Or via the link Or via the link The event code for the mobile application is **bps2022**. To login the mobile app, please use the credentials that have been sent to you via e-mail before the annual meeting.

## DISCLAIMER

### Liability & Insurance

The Meeting Secretariat and Organisers cannot accept liability for personal accidents or loss of or damage to private property of participants. Upon registration, participants agree that neither the BPS Council, the Organising Committee nor the Meeting Secretariat assumes any liabilities.

### Safety and Security

Bags and/or suitcases must not be left unattended at any time whether inside or outside the meeting venue and session halls. As all hotels do, we strongly recommend our participants to use their safety deposit boxes for their valuables.



## INVITED SPEAKERS & SESSION CHAIRS

The invited speakers and session chairs are listed in alphabetical order of their last names for each country. Please visit the Annual Meeting website for full biographies of the invited speakers.

### AUSTRALIA

Rachelle Buchbinder

### CANADA

Anuj Bhatia  
 Kathryn Birnie  
 Melanie Noel  
 Owen D Williamson

### FRANCE

Gisele Pickering

### GERMANY

Esther Pogatzki-Zahn

### INDIA

Amod Manocha

### IRELAND

Elaine Clear  
 Amy Donnelly  
 Dominic Hegarty

### NETHERLANDS

Nathan Hutting

### UNITED KINGDOM

Sam Ahmedzai  
 Nicholas Robert Ambler  
 Anna Andreou  
 Arun Bhaskar  
 Nicola Bryan  
 Gautam Chawla  
 Frances Cole  
 Felicia Cox  
 Emma Davies  
 Diarmuid Denny  
 Anthony Dickenson  
 Rui Duarte  
 Sam Eldabe  
 Mark Farmer  
 Martin Galligan  
 Mahdi Ghomi  
 Ian Goodall  
 Sumit Gulati  
 Ashish Gulve  
 Lauren Heathcote  
 Harry Hebert  
 Mike Hutton  
 Clair Jacobs  
 Selina Johnson  
 Tim Johnson  
 Iain Jones  
 Deborah Joy  
 Edmund Keogh  
 Roger Knaggs  
 Lucie Knight  
 Giorgio Lambro  
 Bertie Leigh

Donna-Marie Lord  
 Manjit Matharu  
 Andrew Moore  
 Neil O'Connell  
 John O'Sullivan  
 Nicholas Padfield  
 David Pang  
 Cathy Price  
 Tara Renton  
 Georgia Richards  
 Raj Sengupta  
 Ashish Shetty  
 Mike Sidery  
 Manojit Sinha  
 Sarah Stanton  
 Johanna Theron  
 Simon Thomson  
 Jonathan Tomlinson  
 Glyn Towler  
 Louise Trewern  
 Jackie Walumbe  
 Stephen Ward  
 Mark Weatherall  
 Martin Wilby  
 Paul Wilkinson  
 Lesley Wright  
 Joanna Zakrzewska

### UNITED STATES

Steven P. Cohen  
 Alexandre DaSilva  
 Timothy Ray Deer



# SCIENTIFIC PROGRAMME

## MONDAY, 13 JUNE 2022

Legend	Plenary Sessions	Parallel Sessions	Industry Satellite Symposia	Society Meetings
Time Slot	HALL A	HALL B	HALL C	HALL D
09:45 - 10:10	<p><b>Welcome</b></p> <p><b>Arun Bhaskar (BPS President)</b> with Tribute to Dr William Campbell</p> <p><b>Stephen Ward (BPS SPC Chair)</b></p>			
10:10 - 10:50	<p><b>Plenary Session 1</b> <b>BPS Lecture</b> <i>Chair: Arun Bhaskar</i></p> <p>Innovation in spine and nerve treatment (Is less more?) <b>Timothy R. Deer</b></p>			
10:50 - 11:20	COFFEE BREAK			
11:20 - 12:30	<p><b>Topical Plenary 2</b> <b>Low Back Pain</b> <i>Chair: Paul Cameron</i></p> <p>Modifying the Matrix: Virtual Reality and Low Back Pain <b>Owen Williamson</b></p> <p>Understanding Inflammatory Back Pain <b>Raj Sengupta</b></p>			
12:35 - 13:55	LUNCH BREAK / BOOTH APPOINTMENTS			
12:50 - 13:50	<p>Industry Satellite Symposium 1 <b>TRPV-1, from Receptor to Results</b> <i>Chair: Anthony Dickenson</i></p> <p>TRPV research - latest advances, <b>Anthony Dickenson</b></p> <p>TRPV-1 research - what does it mean for clinical practice, <b>Dev Tilak</b></p> <p>TRPV research - what the future holds, <b>Anthony Dickenson</b></p>			
13:55 - 15:15	<p><b>Parallel Session A1:</b> <b>Understanding and managing pain: Opioids after surgery: An international co-produced patient information project launch</b> <i>Chairs: Felicia Cox &amp; Roger Knaggs</i></p> <p>Opioid Awareness: An issue not just for clinicians, <b>Amy Donnelly</b></p> <p>Lessons from co-production and design, <b>Louise Trewern, Frances Cole</b></p> <p>Making change happen – putting evidence into practice, <b>Elaine Clear</b></p>	<p><b>Parallel Session A2:</b> <b>The future of pain management programmes following NICE guidelines</b> <i>Chairs: Donna-Marie Lord &amp; Iain Jones</i></p> <p>What puts PMPs at risk from NICE guidelines, <b>Donna-Marie Lord</b></p> <p>The changing face of PMP evidence in the content of the virtual world: outcomes from the Walton Centre, <b>Selina Johnson</b></p> <p>PMPs – their future moving forward: a blended model? <b>John O'Sullivan</b></p>	<p><b>Parallel Session A3:</b> <b>The social and intergenerational context of childhood pain: How parents confer risk and resilience</b> <i>Chair: Edmund Keogh</i></p> <p>The intergenerational transmission of pain in families: An examination of veterans, spouses, and their children, <b>Melanie Noel</b></p> <p>Need and evidence for treating chronic pain in the family, <b>Kathryn Birnie</b></p> <p>How parent body mindsets confer risk in the context of youth with chronic pain, <b>Lauren Heathcote</b></p>	<p><b>Parallel Session A4:</b> <b>Developing the pain workforce – Pain education SIG</b> <i>Chair: Martin Galligan</i></p> <p>Advanced Clinical Practice Pathway for pain clinicians what do you need? <b>Martin Galligan</b></p> <p>Harnessing patients to deliver care - does it work? <b>Nick Ambler,</b> <b>Nicola Bryan</b></p> <p>Working with IAPT, <b>Debbie Joy/Mahdi Ghomi</b></p>
15:15 - 15:45	COFFEE BREAK			



# SCIENTIFIC PROGRAMME

## MONDAY, 13 JUNE 2022

Legend	Plenary Sessions	Parallel Sessions	Industry Satellite Symposia	Society Meetings
Time Slot	HALL A	HALL B	HALL C	HALL D
15:45 - 16:45	<b>Meet the Experts</b> <b>Ultrasound imaging for common pain problems</b> <i>Manojit Sinha, Ashish Shetty, Amod Manocha</i>	<b>Meet the Experts</b> <b>Supported Self-Management</b> <i>Louise Trewern, Mark Farmer, Nathan Hutting</i>	<b>Meet the Experts</b> <b>Musculoskeletal Examination techniques</b> <i>Jackie Walumbe, Diarmaid Denny, Ian Goodall</i>	<b>Meet the Experts</b> <b>How to run an effective PMP</b> <i>Lucie Knight, Clair Jacobs</i>
15:45 - 16:45	<b>Booth Appointments</b> <b>Poster Viewing</b>			
16:45 - 16:55	BREAK			
16:55 - 17:55	<b>Poster Oral Presentations</b> <i>Chair: Stephen Ward</i>  Capturing the Chronic Pain Patient Experience Using a Novel Digital Health Ecosystem, <b>Simon Thomson</b> Mindfulness for adults with chronic low back pain, <b>Michelle Barrow</b> Chronic back pain sub-grouped via psychosocial, brain and physical factors using machine learning: a UKBioBank study of 19,803 adults, <b>Scott Tagliaferri</b> An investigation of behavioural experiments on pain management programmes, Emma <b>Louise Harrold</b> Multifidus Stimulation in Patients with Refractory Chronic Low Back Pain and Functional Spine Instability – Three-Year Pivotal Trial Results, <b>Vivek Mehta</b>			
17:55 - 18:00	BREAK			
18:00 - 19:00	<b>Welcome Reception</b>  <b>Booth Appointments</b> <b>Poster Viewing</b>		<b>Primary &amp; Community Care SIG</b> <b>Business Meeting</b> <i>Chair: James Huddy</i>	<b>Pain Management Programmes SIG</b> <b>Business Meeting</b> <i>Chair: Iain Jones</i>



# SCIENTIFIC PROGRAMME

## TUESDAY, 14 JUNE 2022

Legend	Plenary Sessions	Parallel Sessions	Industry Satellite Symposia	Society Meetings
Time Slot	HALL A	HALL B	HALL C	HALL D
08:00 - 09:00	Industry Satellite Symposium 2 <b>Pathophysiology and Current Treatment options for Mechanical Chronic Low Back Pain</b>  <b>Ashish Gulve</b> <b>Simon Thomson</b> <b>Vivek Mehta</b>			
09:00 - 09:10	BREAK			
09:10 - 10:20	<b>Plenary Session 3</b> <b>Promising New Treatments</b> <i>Chair: Roger Knaggs</i>  Pharmacological treatments for pain – is there anything in the pipeline? <b>Gisèle Pickering</b>  Artificial Intelligence and Augmented Reality for Orofacial Pain: Revolutionising Pain Research, Education and Treatment <b>Alexandre DaSilva</b>			
10:20 - 10:50	COFFEE BREAK			
10:50 - 12:10	<b>Parallel Session B1:</b> <b>Opioid epidemiology in practice; What does it mean for primary care</b> <i>Chairs: Georgia Richards, Johanna Theron</i>  The epidemiology of opioids in the UK, <b>Georgia Richards</b> with contributions from <b>Emma Davies</b> and <b>Harry Herbert</b> The East Kent targeted primary care opioid reduction project - the first year, <b>Johanna Theron</b> Multi-disciplinary medicines management in the secure environment: the East Kent experience, <b>Lesley Wright</b> Call to action for the national registry of opioid safety initiatives, <b>Georgia Richards</b>	<b>Parallel Session B2:</b> <b>This house believes - Is it not possible to consent and still meet the legal requirements</b> <i>Chairs: Glyn Towleron</i>  Updates on medical consent, <b>Bertie Leigh</b> For the motion, <b>Michael Sidery</b> Against the motion, <b>Nicholas Padfield</b> For the motion, <b>Sarah Stanton</b> Against the motion, <b>Gautam Chawla</b> Cross examination	<b>Parallel Session B3:</b> <b>Dilemmas in Pain Management – and interactive discussion (Philosophy and Ethics SIG)</b> <i>Chair: Tim Johnson</i>  Panelists: <b>Jonathan Tomlinson</b> <b>Paul Wilkinson</b> <b>Felicia Cox</b>  Please submit your dilemmas before the session on the website.	<b>Parallel Session B4:</b> <b>Management of Headaches</b> <i>Chair: Anna Andreou</i>  Migraine: Real world evidence on the efficacy and safety of CGRP Abs in migraine, <b>Georgio Lambru</b> NICE approvals and criteria for the use of CGRP mAbs in migraine, <b>Mark Weatherall</b> Minimally invasive interventions for headaches, <b>Manjit Matharu</b>
12:10 - 13:40	LUNCH BREAK / BOOTH APPOINTMENTS			



# SCIENTIFIC PROGRAMME

## TUESDAY, 14 JUNE 2022

Legend	Plenary Sessions	Parallel Sessions	Industry Satellite Symposia	Society Meetings
Time Slot	HALL A	HALL B	HALL C	HALL D
12:30 - 13:30	Industry Satellite Symposium 3 <b>Neuromodulation: Who, Why &amp; When</b>			
13:40 - 14:55	<b>Plenary Session 4</b> <b>Making a difference for children in pain</b> <i>Chair: Edmund Keogh</i>  Remembering the pain of childhood, <b>Melanie Noel</b> Partnering for pain: Transforming pediatric pain through patient and family partnership, <b>Katie Birnie</b>			
14:55 - 15:05	BREAK			
15:05 - 16:25	<b>Parallel Session C1:</b> <b>Back Pain Updates</b> <i>Chair: Cathy Price</i>  NERVES trial outcomes - do we need discectomy? <b>Martin Wilby</b> Spinal Pathways 2022, <b>Mike Hutton</b>	<b>Parallel Session C2:</b> <b>Interventional Pain SIG – All about the joints</b> <i>Chair: Sumit Gulati</i>  RF for Shoulder, <b>Dominic Hegarty</b> RF for Knees, <b>Steve Cohen</b> RF for Hips, <b>Anuj Bhatia</b> Panelist: <b>Arun Bhaskar</b>	<b>Parallel Session C3:</b> <b>Pharmacology and basic science</b> <i>Chair: Anthony Dickenson</i>  Advancing the pharmacology of pain, <b>Anthony Dickenson</b> Ketamine - useful or dangerous? <b>Gisele Pickering</b> Prevention of Chronic pain – translational pain research, <b>Esther Pogatzki-Zahn</b>	
16:25 - 16:55	COFFEE BREAK			
16:55 - 18:10	<b>Plenary Session 5</b> <b>Debate: This House Believes that Pain Medications do More Harm than Good</b> <i>Chair: Stephen Ward</i>  For: <b>Rachelle Buchbinder</b>  Against: <b>Andrew Moore</b>			
18:10 - 19:10	<b>Industry Exhibition</b> Poster Viewing		<b>Pain in Developing Countries SIG</b> <b>Business meeting</b> <i>Chair: Vicky Tidman</i>	<b>Interventional Pain Medicine SIG</b> <b>Business meeting</b> <i>Chair: Sumit Gulati</i>



## SCIENTIFIC PROGRAMME

### WEDNESDAY, 15 JUNE 2022

Legend	Plenary Sessions	Parallel Sessions	Industry Satellite Symposia	Society Meetings
Time Slot	HALL A	HALL B	HALL C	HALL D
08:00 - 09:10	<b>Plenary Session 6            Headache &amp; Facial Pain</b> <i>Chair: Joanna Zakrzewska</i>  The Diagnosis and Management of Common Headache Problems <b>Giorgio Lambru</b>  Understanding Orofacial Pain <b>Tara Renton</b>			
09:10 - 10:10	Industry Satellite Symposium 4 <b>The Role of the HCP in the            management of Headache in the new            Headache and Facial Pain Pathway</b>			
10:10 - 10:40	COFFEE BREAK			
10:40 - 12:00	<b>Parallel Session D1:            Practical pain management            for Cancer Pain</b> <i>Chair: Sam Ahmedzai</i>  Cancer pain – pharmacology, <b>Sam Ahmedzai</b> Cancer pain – ablative treatments, <b>Arun Bhaskar</b> Neuromodulation in Cancer Survivors, <b>Ashish Gulve</b>	<b>Parallel Session D2:            Management of difficult facial pain</b> <i>Chair: Joanna Zakrzewska</i>  National guidelines for managment of TN, <b>Joanna Zakrzewska</b> Refractory orofacial pain, <b>Tara Renton</b> New approaches to treatment of orofacial pain, <b>Alexandre DaSilva</b>	<b>Parallel Session D3:            Trust and validity in pain evidence</b> <i>Chair: Stephen Ward</i>  <b>Neil O Connell</b> <b>Andrew Moore</b>	<b>Parallel Session D4:            Stimulation 2022</b> <i>Chair: David Pang</i>  Who does best with neuromodulation, <b>Simon Thomson</b> Failed back surgery how common and what is the cost? <b>Sam Eldabe</b> Access to neuromodulation in England in the last 10 years. HES Analysis, <b>Rui Duarte</b>
12:00 - 13:15	LUNCH BREAK / BOOTH APPOINTMENTS			
13:15 - 14:45	<b>AGM</b>			
14:45 - 15:25	<b>Plenary Session 7            Pat Wall Lecture</b> <i>Chair: Arun Bhaskar</i>  Pre-Clinical research: Why is it so difficult to translate into practice? <b>Esther Pogatzki-Zahn</b>			
15:25 - 15:40	<b>Poster Awards &amp; Closing Ceremony</b>			



## INDUSTRY SYMPOSIA

### Industry Sponsored Symposium 1:

#### TRPV-1, from Receptor to Results

**Date** : Monday, 13 June 2022

**Time** : 12:50 - 13:50

**Hall** : Hall A

**Moderator** : Prof Anthony Dickenson

**Speakers** :

TRPV research - latest advances, **Prof Anthony Dickenson**

TRPV-1 research - what does it mean for clinical practice, **Dr Dev Tilak**

TRPV research - what the future holds, **Prof Anthony Dickenson**



### Industry Sponsored Symposium 2:

#### Pathophysiology and Current Treatment options for Mechanical Chronic Low Back Pain

**Date** : Tuesday, 14 June 2022

**Time** : 08:00 - 09:00

**Hall** : Hall A

**Speakers** :

**Ashish Gulve**, James Cook University Hospital, Middlesbrough

**Simon Thomson**, Basildon University Hospital, Basildon

**Vivek Mehta**, St Bartholomew's and Royal London Hospital, London





## INDUSTRY SYMPOSIA

### Industry Sponsored Symposium 3:

#### Neuromodulation: Who, Why & When

**Date** : Tuesday, 14 June 2022

**Time** : 12:30 - 13:30

**Hall** : Hall A

**Moderator** : Neil Collighan

**Speaker** : Tina Elliott



### Industry Sponsored Symposium 4:

#### How to successfully implement a new optimal clinical pathway: Headache and facial pain in practice

**Date** : Wednesday, 15 June 2022

**Time** : 09:10 - 10:10

**Hall** : Hall A

**Moderator** : Arun Bhaskar, Mark Weatherall

**Speakers** : Ria Bhola, Vivek Mehta, Rob Music, Arvind Madan





## SPONSORS & EXHIBITORS

### PLATINUM



### SILVER



### GOLD



### SPONSORS & EXHIBITORS





## INDUSTRY COMPANY PROFILES

### Abbott

Web : [www.abbott.com](http://www.abbott.com)

At Abbott, we understand how the search for effective pain relief can impact peoples' lives. But we believe that pain management is possible, no matter how long that pain has affected your life. And we're committed to providing resources and therapy for people managing pain with many causes, in many parts of their body. That's why at Abbott, we're driven to provide you with the tools and support you need to get your patients living full lives again. Our technology for treating chronic pain and movement disorders delivers innovative therapies focused on reliving and reducing the physical and mental toll these conditions can take on your patients.



### Advanced Medical Equipment Ltd

Address : Unit 4, Foundry Court, Foundry Lane, Horsham,  
 West Sussex, RH13 5PY, U.K.  
 Phone : 01403 260156  
 Web : [www.advancedmedicalequipment.com](http://www.advancedmedicalequipment.com)

Advanced Medical Equipment Ltd. is a British company based in Horsham, West Sussex, U.K. Founded in 2002, it specializes in the distribution of advanced technology, providing equipment, services, and consumables for medical, clinical and research use, mainly in the Neurology field.

We are the exclusive distributor of Medoc Advanced Medical Systems for the U.K. and Ireland.

Medoc, established in 1990, is a leading developer and manufacturer of neuro-diagnostic medical systems used to assess and monitor acute and chronic pain.

Their products are based on technologies that test and evaluate the function of small and large peripheral sensory nerve fibres.

Specialties:

Pain, Peripheral Neuropathies, Pain Imaging (fMRI), Pharmaceutical Trials, Small-fibre Evoked Potentials, Evoked Potential, Conditioned Pain Modulation, CPM, Neurosensory Analyzer, Thermal testing, CHEPS, Sensory testing, QST, Diabetic neuropathy, Small-fibre neuropathy



### ALTHEA UK

Address : 19 EASTBOURNE TERRACE; PADDINGTON STATION; W2 6LG  
 Phone : +44 (0) 203 983 0888  
 Web : [www.althea.life](http://www.althea.life)

Althea is a leading global medical cannabis pharmaceutical company. We are dedicated to improving the lives of people suffering from debilitating illnesses through the supply of medical cannabis products and the education of healthcare professionals. Althea's UK operation was founded in February 2019, with the aim of providing pharmaceutical grade unlicensed medical cannabis products to eligible patients within the UK. We also offer education and resources for healthcare professionals. Althea's ambition is to be a leading global pharma company focused on innovation and specialist care.





## INDUSTRY COMPANY PROFILES

### Boston Scientific

Web : Advancing Science for Life - US - Boston Scientific



A global leader in microelectronic implantable technologies for chronic pain. We understand that chronic pain and neurological diseases can be debilitating for patients. That's why we're dedicated to working closely with both physicians and patients to develop meaningful, industry-leading solutions that can improve the quality of life for millions worldwide.

**Personalizing Pain Therapy.** Pain is personal. That's why we designed the Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System to provide personalized, long-lasting pain relief through the power of combination therapy, the technology of novel sub-perception algorithms and the simplicity of wave for automation.

**Technology-Leading Radiofrequency Ablation.** We offer radiofrequency ablation (RFA) systems used by physicians to treat patients with chronic pain. RFA is a versatile outpatient procedure that is often used prior to SCS in the treatment continuum for chronic pain and has a more than 50-year track record of providing relief for patients with chronic pain.

### BVM Medical Limited

Phone : 01455 614 555  
 Web : www.BVMMedical.com



BVM Medical Limited was established July 1989 and is a distributor of Medical Devices.

Our Mission Statement is to help improve patient care and treatment outcomes by introducing innovative and latest technology, disposable and implantable medical devices to Clinicians.

Our Working Practices will embrace the following:

- We will provide 24 hours a day service to Clinicians who wish to work with our devices.
- We will conduct our business ethically
- We will give a little back by helping others less fortunate

Clinical Specialities:

- Interventional Congenital and Structural Cardiology
- Interventional Radiology
- Gastroenterology
- Vascular Surgery
- Pain Management - Cryo-analgesia



## INDUSTRY COMPANY PROFILES

### Grow Pharma Ltd

Web : <https://growgroupplc.com/>

Many patients in chronic or end of life care could potentially benefit from managing their symptoms with medical cannabis. Grow Pharma is a leader in unlicensed medicinal cannabis. Our aim is to educate healthcare professionals about this option and to provide them and their patients with a stable supply and wide range of high-quality cannabis medicines, including flowers, oils, capsules and vapes.

Grow Pharma has a comprehensive suite of services to help HCPs with the practicalities of prescribing cannabis medicines: educational webinars, MSL support, doctor portal, Journal club are all aimed at supporting you when prescribing cannabis medicines.

At Grow Pharma we put patients at the heart of everything we do, because every patient matters. Contact us via our website contact form: [www.growgroupplc.com/for-doctors/](http://www.growgroupplc.com/for-doctors/)



### Grünenthal Limited

Address : Unit 1, Stokenchurch Business Park Ibstone Road,  
 Stokenchurch , HP14 3FE

Phone : 07494 486 240

Web : [www.grunenthal.co.uk](http://www.grunenthal.co.uk)

Grünenthal is a global leader in pain management and related diseases.

As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. We are present in 29 countries with products sold in more than 100 countries. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain.

M-N/A-UK-03-22-0007 – March 2022



### Khiron

Khiron is a leading global medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and focus on creating access to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Germany, UK, Peru, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.





## INDUSTRY COMPANY PROFILES

### Medical Research Foundation

Address : 99 Charterhouse Street, London, EC1M 6HR  
 Phone : 0207 395 2400  
 Web : [www.medicalresearchfoundation.org.uk](http://www.medicalresearchfoundation.org.uk)



At the Medical Research Foundation, we have been funding life-changing medical research for over 100 years.

Through our connection with the Medical Research Council, we have access to some of the best medical knowledge in the world. But as an independent charity, we are extremely flexible, responding to emerging health needs as they arise, and funding the research that is needed to change lives.

We are already supporting the next generation of leaders in pain research, and we have exciting plans to fund more in the future, including researchers working in child and adolescent cancer pain, and musculoskeletal pain.

### Medtronic

Web : [medtronic.com](http://medtronic.com)

Bold thinking. Bolder actions. We are Medtronic.

We lead global healthcare technology and boldly attack the most challenging health problems facing humanity by searching out and finding solutions. Our Mission – to alleviate pain, restore health, and extend life – unites a global team of 90,000+ passionate people.

Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world.

In everything we do, we are engineering the extraordinary.



### Nevro

Address : 1800 Bridge Parkway ,Redwood City ,94065,USA  
 Web : [www.nevro.com](http://www.nevro.com)



Nevro is a global medical device company headquartered in Redwood City, CA that has the simple goal of helping more patients suffering from chronic pain including painful diabetic neuropathy (PDN) achieve lasting relief. Nevro offers a next-generation advanced therapy called HFX. Built on the outcomes of 80,000+ patients, HFX is the most effective treatment for painful diabetic neuropathy patients refractory to conventional medical treatment.



## INDUSTRY COMPANY PROFILES

### Oncomfort S.A

Web : Oncomfort Digital Sedation™

Oncomfort Digital Sedation™ is a completely new, safe and effective digital therapy to manage patients' pain and anxiety before, during and after medical procedures, without medication.

This revolutionising digital therapy combines clinical hypnotherapy and integrative therapeutic techniques through Virtual Reality.

The application has been co-created with multidisciplinary medical experts having deep clinical and scientific knowledge in this field.



### Pfizer: Breakthroughs That Change Patients' Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS. To learn more about our commitments, please visit us at [www.pfizer.co.uk](http://www.pfizer.co.uk) or follow us on Twitter (@Pfizer\_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).



### Polar Medical Ltd

Address : Cole House\ Bethersden TN26 3AT  
 Phone : 01233 822069  
 Web : [www.polarmedical.co.uk](http://www.polarmedical.co.uk)



Polar Medical Ltd was incorporated on 1st December 2015, and VAT registered as of June 2016. Our ethos is simple – “To offer a high level of service with an attention to detail that will facilitate repeat business and growth moving forward, through the supply of niche market, high value Radiofrequency devices.”

Polar Medical is dedicated to the supply of specialised Chronic Pain reducing Medical Devices.

We have products for Radio-Frequency Denervation of the Spine and Large Joints, and DBS (Deep Brain Stimulation), DREZ and Cordotomy for Intractable Pain.

We have access to an Arc Laser Discectomy Device and are working with PD Neuro Technology on supplying a Parkinson's Disease Wearable Monitoring system.

Based in the South-East of England, we have excellent coverage for the UK with our company representatives covering Scotland, North of England, the Midlands, North London and the South of England.

Being ISO 9001:2015 and ISO 13485:2016 certified, you can be sure of a professional service, tailored to each customer's needs and requirements.

We can be contacted through our website ([www.polarmedical.co.uk](http://www.polarmedical.co.uk)), either via email, office landline or mobile telephone.



## INDUSTRY COMPANY PROFILES

### Q Interventional Technologies Ltd

Web : [www.qitec.co.uk](http://www.qitec.co.uk)

Q Interventional Technologies are led by a team who have many years' experience and partner with companies from across the globe to bring clinically proven devices for the treatment of chronic pain, to Interventional Pain Management specialists, Spinal and Neurosurgeons, Anaesthesiologists, and Interventional Radiologists in the United Kingdom & Ireland.

Our mission is a simple one; to offer a suite of products and services, representing the highest levels of quality, efficacy & safety that deliver great outcomes for patients & practitioners in Interventional Pain Management therapy.



### Rokshaw Limited

With a full range of UK manufactured EU-GMP full spectrum oils and flower products, containing varying levels of THC & CBD content, Rokshaw Laboratories is the MHRA-approved Specials manufacturer making medical cannabis more accessible and affordable than ever before.

Rokshaw is part of Curaleaf International, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Our wealth of medical cannabis experience, combined with a network of supply and distribution partnerships throughout Europe, means that Rokshaw is uniquely positioned to meet the rapidly growing demand for cost-effective, consistent, premium quality medical cannabis products in the UK.



### Sandoz, a Novartis division

Address : Park View, Riverside Way, Watchmoor Park, Camberley, Surrey GU15 3YL  
 Phone : +44 1276 698 101  
 Web : [www.sandoz.uk.com](http://www.sandoz.uk.com)



Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercialising affordable medicines. In 2020, we saved the NHS an estimated £1.2 billion through the provision of generic and biosimilar alternatives to patented medicines. With our broad portfolio of medicines, we reach approximately 421,000 patients per month<sup>1</sup>.

Our ambition is to establish Sandoz UK as the leading partner to deliver exceptional value for our customers and patients.

<sup>1</sup>Sandoz Fast Facts – 2020 (September 2021 | 158909)

Prescribing information for RIZMOIC® (naldemedine) can be found here: <https://www.sandozhub.co.uk/sites/sandozhub.co.uk/files/Rizmoic-PI.pdf>



## INDUSTRY COMPANY PROFILES

### Stimwave Technologies

Address : 1310 Park Central Blvd S, Pompano Beach, Florida, 33064  
 Phone : +1 800.965.5134  
 Web : [www.Stimwavefreedom.com](http://www.Stimwavefreedom.com)

Stimwave is a neuromodulation company cleared by the FDA and CE marked for a revolutionary, micro-invasive, IPG-free device to help patients reduce their chronic neuropathic pain by pinpointing stimulation directly to the affected peripheral nerves with a multi-electrode, programmable device which enables ongoing MRI scans.



### Stryker

Address : Stryker House Hambridge Road Newbury Berkshire RG14 5AW  
 Phone : +44 1635262400  
 Web : <https://www.stryker.com/>

Stryker Interventional Spine is driven to make healthcare better. We provide an extensive and a tailored product portfolio for vertebral augmentation and radiofrequency ablation procedures, along with a diagnostic tool and decompression treatment for contained disc herniations. Our team delivers high quality personalized education programs designed to advance minimally invasive surgical techniques. You can count on us to support your success and drive value through training focusing on the correct clinical and technical application of our products and procedures. From the office to the operating room and every stop in between, we are here to serve you with a portfolio built on innovation and a legacy of customer service.



### The Royal Marsden

E-mail : [conferenceteam@rmh.nhs.uk](mailto:conferenceteam@rmh.nhs.uk)  
 Phone : 020 7808 2921  
 Web : [www.royalmarsden.nhs.uk/studydays](http://www.royalmarsden.nhs.uk/studydays)

Specialists in conferences and events management  
 The Royal Marsden Conference Team organises world-class medical conferences, study and training days for The Royal Marsden NHS Foundation Trust and other healthcare institutions. We offer an experienced and dedicated event management team who organise conferences both at The Royal Marsden and externally.





## INDUSTRY COMPANY PROFILES

### THOR Photomedicine (THOR)

Address : Water Meadow House, Chesham, Buckinghamshire HP5 1LF  
Phone : +44 (0)1494 797 100  
Web : <https://www.novothor.com> <https://www.thorlaser.com>



THOR is an expert Photobiomodulation (PBM) company. PBM is a light therapy shown to reduce inflammation and pain wherever the beam is applied. Hundreds of RCTs and systematic reviews report that PBM has a positive impact on relieving musculoskeletal and neuropathic pain, with subsequent improvement in the quality of life. PBM has also been shown to reduce the incidence and severity of Oral Mucositis and is recommended in National Institute for Health and Care Excellence (NICE) guidelines.

# IONICRF™ GENERATOR



FASTER. TREAT UP TO  
FOUR SITES AT ONCE.

## RELIEF, REIMAGINED.

The IonicRF™ Generator, Abbott's latest innovation, continues our evolution of RF therapy technology. The generator's durable and ergonomic architecture was developed with two goals in mind. To combine optimal system reliability with high-efficiency performance.

MORE INFORMATION IS AVAILABLE AT [NEUROMODULATION.ABBOTT](https://www.neuromodulation.abbott)

#### Abbott

One St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000  
[Neuromodulation.Abbott](https://www.neuromodulation.abbott)

#### Rx Only

**Brief Summary:** Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

™ Indicates a trademark of the Abbott group of companies.

© 2020 Abbott. All Rights Reserved.

MAT-2005122 v2.0 | Item approved for global use.



# Qutenza®

capsaicin 179 mg patch

## TREATING PNP: TIME FOR A DIFFERENT PERSPECTIVE

### TIME FOR QUTENZA

- A single topical intervention that can maintain pain reduction for up to 12 weeks<sup>1-4</sup>
- Sustained pain reduction for up to 52 weeks following initial and repeated treatments<sup>5</sup>
- Topical efficacy comparable to oral pregabalin<sup>6</sup>
- Reduced treatment burden and lower rate of systemic side effects compared with oral pregabalin<sup>6,7</sup>

**QUTENZA is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain.<sup>8</sup>**



**References:** 1. Simpson DM et al. *Neurology* 2008;70:2305-2313. 2. Backonja M et al. *Lancet Neurology* 2008;7:1106-1112. 3. Simpson DM et al. *J Pain* 2017;18:42-53. 4. Mailhofner C & Heskamp ML. *Current Medical Research and Opinion*. 2013;29:673-683. 5. Mankowski C, et al. *BMC Neurology*. 2017;17:80. 6. Haanpää M, et al. *Eur J Pain*. 2016;20:316-328. 7. Abdulhadi AK, et al. *Contemp Clin Trials* 2016;4:186-191. 8. QUTENZA Summary of Product Characteristics.

**Qutenza® (capsaicin) Prescribing Information. Refer to the respective CB or NI Summary of Product Characteristics (SmPC) before prescribing - available at <https://www.medicines.org.uk>.** **Presentation:** Qutenza 179 mg cutaneous patch. Each 280 cm<sup>2</sup> cutaneous patch contains a total of 179 mg of capsaicin or 640 micrograms of capsaicin per cm<sup>2</sup> of patch. Excipient with known effect: Each 50g tube of cleansing gel for Qutenza contains 0.2mg/g butylhydroxyanisole (E320). **Indications:** Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain. **Posology and method of administration:** The Qutenza cutaneous patch should be applied by a physician or a healthcare professional under a physician's supervision in a well ventilated treatment area. The cutaneous patch should be applied to the most painful skin areas (up to a maximum of 4 patches). The painful area should be determined by the physician or by healthcare professional and marked on the skin. Nitrile gloves should be worn at all times while handling Qutenza and cleaning treatment areas. Latex gloves should NOT be worn as they do not provide adequate protection. Use of a mask and protective glasses is recommended, particularly during application and removal of the patch. The area may be pre-treated with a topical anaesthetic or the patient may be administered an oral analgesic prior to application of Qutenza to reduce potential application related discomfort. Topical anaesthetics should be removed prior to applying Qutenza and the skin washed and dried thoroughly. If necessary, hair should be clipped, not shaved. Qutenza must be applied to intact (unbroken), non-irritated, dry skin, and allowed to remain in place for 30 minutes for the feet (e.g. HIV-associated neuropathy, painful diabetic peripheral neuropathy [pDPN]) and 60 minutes for other locations (e.g. post-herpetic neuralgia). When removing the patches they should be rolled inwards to minimise the risk of aerosolisation of capsaicin. Cleansing gel should be used to remove residual capsaicin and should be left on the area for at least one minute, wiped off and the area subsequently washed with soap and water. Patients experiencing pain during and after patch application should be provided with supportive treatment. Qutenza treatments may be repeated every 90 days, as warranted by the persistence or return of pain. Re-treatment after less than 90 days can be considered for individual patients only after a careful assessment by the physician. A minimum interval of 60 days between treatments is to be observed. **Paediatric population:** Qutenza is not recommended

for use in children and adolescents (birth to 18 years) due to lack of data on safety and efficacy. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Special warnings and precautions:** **Dermal assessment:** Qutenza must be used only on dry, intact skin (unbroken) and not on the face, above the hairline of the scalp, and/or in proximity to the eyes or mucous membranes. In patients with pDPN, a careful visual examination of the feet should be undertaken prior to each application of Qutenza and at subsequent clinic visits to detect skin lesions related to underlying neuropathy and vascular insufficiency. **Sensory function:** Reductions in sensory function have been reported following administration of Qutenza. All patients with pre-existing sensory deficits should be clinically assessed for signs of sensory loss prior to each application of Qutenza. Caution should be exercised in patients with reduced sensations in the feet and in those at increased risk for such changes in sensory function. If sensory loss is detected or worsens, Qutenza treatment should be reconsidered. **Application site reactions:** Transient local application site burning, pain, erythema and pruritus are common/very common. In addition, cases of burns have been reported, including second degree burns in patients treated with capsaicin patches. In patients reporting severe pain, the patch should be removed and the skin examined for chemical burn. The cleansing gel for Qutenza contains butylhydroxyanisole, which may cause local skin reactions (e.g. contact dermatitis) or irritation of eyes and mucous membranes. **Unintended exposure:** Unintended exposure to capsaicin may cause irritation of eyes, mucous membranes, respiratory tract, and skin in patients and healthcare professionals. If Qutenza comes in contact with skin not intended to be treated, cleansing gel should be applied. If capsaicin comes in contact with eyes or mucous membranes, flush with cold water. If irritation of airways, eyes or mucous membranes occurs the affected individual should leave the Qutenza treatment area. Treat shortness of breath with appropriate medical care. If respiratory irritation worsens or does not resolve, Qutenza treatment should be reconsidered. **Increase in blood pressure:** Blood pressure should be monitored during the treatment procedure as transient increases (average <8.0mmHg) in blood pressure during and shortly after Qutenza treatment may occur due to the treatment related increase in pain. The risk of adverse cardiovascular reactions due to the potential stress of the procedure should be considered prior to using Qutenza in patients with unstable or poorly controlled hypertension, history of cardiovascular events and particularly in diabetic patients with coronary artery disease, hypertension and cardiovascular autonomic neuropathy. **Treatment-related discomfort:** Patients experiencing pain during and after patch application should be provided with supportive treatment such as local cooling (such as a cool compress) or oral analgesics (i.e. short-acting opioids). **Opioid tolerance:** Patients using high doses of opioids may not respond to oral opioids when used for acute pain during and following treatment with Qutenza. An

alternative pain reduction strategy should be used when high opioid tolerance is suspected. **Interactions:** No formal interaction studies with other medicinal products have been performed as only transient low levels of systemic absorption have been shown to occur with Qutenza. **Pregnancy, lactation and breast feeding:** Limited clinical data on exposed pregnancies are available. Since human pharmacokinetics show transient, low systemic exposure to capsaicin, the likelihood that Qutenza increases the risk of developmental abnormalities when given to pregnant women is very low. However, caution should be exercised when prescribing to pregnant women. It is unknown whether capsaicin/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Qutenza. **Effects on ability to drive or use machinery:** Qutenza has no or negligible influence on the ability to drive and use machines. **Undesirable effects:** **Very common** (≥ 1/10): application site pain, application site erythema. **Common** (≥ 1/100 to < 1/10): **Application site:** pruritus, papules, vesicles, oedema, swelling, dryness, peripheral oedema. **Others:** burning sensation, hypertension, cough, nausea, pruritus, pain in extremity, muscle spasms. **Uncommon** (≥ 1/1,000 to < 1/100): **Application site:** urticaria, paraesthesia, dermatitis, hyperaesthesia, inflammation, reaction, irritation, bruising. **Others:** throat irritation, first degree atrio-ventricular (AV) block, tachycardia, palpitations, eye irritation, dysgeusia, hypoesthesia, herpes zoster, increased blood pressure (investigations). **Not known:** burns second degree, accidental exposure (including eye pain, eye and throat irritation and cough). Prescribers should consult the SmPC in relation to all adverse reactions. **Overdose:** In case of suspected overdose, the patches should be removed gently, cleansing gel should be applied for one minute and then wiped off with dry gauze and the area should be gently washed with soap and water. Supportive measures should be taken as clinically needed. There is no antidote to capsaicin. **Basic NHS Cost:** Qutenza® 179 mg cutaneous patch plus 50g tube cleansing gel £210 per pack. **Legal Classification:** POM. **Marketing authorisation number(s):** EU/1/09/524/001-002. **Marketing authorisation holder:** Grünenthal GmbH, Zieglerstraße 6, 52078 Aachen, Germany. **Date of preparation:** March 2021. M-QZA-UK-03-21-0008.

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/>  
Adverse events should also be reported to Grünenthal Limited  
Please contact 0870 351 8960 or [medicinalinformationuk@grunenthal.com](mailto:medicinalinformationuk@grunenthal.com)

Qutenza Summary of Product Characteristics. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza#product-information-section>

M-QZA-UK-03-22-0004 – March 2022

“Inhalation of pharmaceutical grade, THC-dominant, cannabis flos improves pain scores and health-related quality of life in UK eligible patients”

E-POSTER #PP098



A LEADING GLOBAL MEDICAL CANNABIS COMPANY

Presenting at the British Pain Society 55<sup>TH</sup> ANNUAL SCIENTIFIC MEETING



### KHIRON 1/14 (God Bud)

Medical Uses:



Migraine



Chronic Pelvic Pain



Cannabis Therapy Initiation



Inflammatory Bowel Disease (IBD)



Stress / Burnout



Substance Use Disorder

### KHIRON 20/1 (Hindu Kush)

Medical Uses:



Chronic Pain



CINV and Anorexia



Tourette's Syndrome



Multiple Sclerosis



Sleep Disorders



PTSD

Featured Product in E-POSTER #PP098



“The aim of the wise is not to secure pleasure, but to avoid pain.”

For more information:  
[www.khironmed.co.uk](http://www.khironmed.co.uk)  
[medical@khironmed.co.uk](mailto:medical@khironmed.co.uk)

Aristotle





# Oncomfort Sedakit™ X for patient-adapted Digital Sedation™

Innovation that brings  
**Digital Sedation™**  
at your fingertips

1

Optimal pain and anxiety relief using validated clinical modules in Virtual Reality

2

Overview and real-time adjustment of the therapeutic session

3

Interaction capability with the patient along the session

Learn more on:  
[www.oncomfort.com](http://www.oncomfort.com)





## MultiGen 2 RF Generator

### The next generation has arrived

Enter the new generation of radiofrequency ablation and discover the control and confidence that the MultiGen2 RF Generator offers.

#### Increase your confidence

Engineered with 100 watts - double the industry standard - the MultiGen2 RF Generator can efficiently achieve a monitored target temperature.

#### Maximize your time and schedule

Procedure designed for quick ramp up time with a single touch of a button. Create a strip lesion without removing electrodes.

#### Embrace a modern mindset

The MultiGen 2 RF Generator is appointed with modern features, like a responsive touchscreen, a USB port for saving and transferring presets and a life cycle tracker for electrode and splitter cable uses.

#### Take command

Choose the order of lesions with independently run channels. Perform at your own pace with flexible stimulation controls. With the MultiGen 2 RF Generator, you can customize your procedure based on patient needs, procedural goals and personal preferences.

# Venom Cannula and Electrode System

## The intersection of efficiency and outcomes

The Venom System provides efficiency, confidence and large lesions while maintaining a small footprint.\*


### Venom multiple configuration

The innovative design offers an alternative configuration with a "V" shaped active tip at the distal end, while it maintains the same gauge size as the standard Stryker configuration. The Venom cannula allows for efficient anesthesia delivery to the targeted nerve through the side port design.<sup>1</sup>


### Work with efficiency

Multiple deployment configurations improve lesion control. Your time and schedule matter. The Venom System enhances both. Improve anesthesia propagation to the target lesion zone with the cannula side port.

### Comparison of average lesion volume produced by Venom and standard RF cannulae<sup>1</sup>



Note: Measurements made in ex vivo chicken breasts.  
Note: measurements above are not to scale



\*Based on 18G Venom Cannula and Electrode System

1. Stryker Corporation. (2017). Effect of Venom Cannula and Electrode System on lesion size and anesthesia delivery during radiofrequency ablation [Clinical white paper, 1000-025-195 Rev A]. Kalamazoo, MI

# Radiofrequency ablation


## Performance Platform

### MultiGen 2 Radiofrequency Generator and Venom Cannula and Electrode System





**THE BRITISH  
PAIN SOCIETY**  
EXPERTISE WHERE IT MATTERS



BRITISH  
PAIN  
SOCIETY  
'22



13 - 15 June 2022  
LONDON & ONLINE